Company profile
Phio Pharmaceuticals Corp.
NASDAQ: PHIO · Healthcare · Biotechnology
PublicHQ Marlborough, PACIK 0001533040Reports USD
#1162 of 1,417 Healthcare companies by revenuebottom-decile growth
EA Score
41DFH 53DQ 42GM 5SS 43
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$8.7M
Employees
6
as of 2026-09-20
Market cap
$12.0M
as of 2026-09-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02020
Net income-$8.7M-$8.7M2025
Operating income-$9.2M-$9.2M2025
Total assets$21.5M$21.5M2025
Liabilities$1.3M$1.3M2025
Equity$20.1M$20.1M2025
Revenue trend
FY2012 – FY2020 · USD
FY12
FY13
FY16
FY16
FY17
FY18
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Phio Pharmaceuticals Corp.’s revenue?
Phio Pharmaceuticals Corp. booked $0 in FY2020 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
BioCardia, Inc.29DAdagio Medical Holdings, Inc.24DSynlogic, Inc.45DSatellos Bioscience Inc.——Captiva Verde Wellness Corp.——Kiora Pharmaceuticals, Inc.51DKey facts
CEORobert L. Bitterman
SectorHealthcare
IndustryBiotechnology
HeadquartersMarlborough, PA
ExchangeNASDAQ: PHIO
Employees6
IPO date2012-05-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.